News Celgene to file potential MS blockbuster this year Success with ozanimod would justify $7.2 billion outlay for Receptos.
News Valeant's Siliq approved but suicidal thoughts warning will ... But drug will have boxed warning over suicidal ideation.
News Trump demands cuts to 'astronomical' drug prices - but pharm... Trump calls pharma leaders to White House to discuss cutting taxes, regulations - and drug prices
News Delinia adds to Celgene's immunology ambitions Celgene continues with focus on autoimmune diseases.
News Celgene broadens immunology presence with Anokion deal Biotech specialises in autoimmune disorder drugs.
News Lilly bags FDA okay for Wegovy pill rival orforglipron Eli Lilly has claimed US approval for oral GLP-1 agonist orforglipron, setting up a market clash with Novo Nordisk's first-to-market Wegovy pill.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
